Emerging Therapeutics for Neurodegenerative Diseases Part II: Huntington's Disease and Amyotrophic Lateral Sclerosis (HD & ALS)
|発行||Frost & Sullivan||商品コード||913123|
|出版日||ページ情報||英文 71 Pages
|神経変性疾患の新興治療法パートII：ハンチントン病、筋萎縮性側索硬化症（HD・ALS） Emerging Therapeutics for Neurodegenerative Diseases Part II: Huntington's Disease and Amyotrophic Lateral Sclerosis (HD & ALS)|
|出版日: 2019年09月17日||ページ情報: 英文 71 Pages||
Novel Targeted Therapeutic Strategies Technologies Around Neurodegenerative Disorders - From Palliative to Future Interventions
At present, only a few therapies are available with relatively low success. Both, the clinical and the scientific communities are critically devoted to develop new therapeutic approaches to treat and diagnose neurodegenerative diseases.
At present days, neurodegenerative diseases represent one of the main causes of death in the industrialized economy. Overall characterized by a loss of neurons in particular regions of the nervous system, the subsequent decline in cognitive and motor function that patients experience in these diseases is associated with nerve cell loss.
The most common denominator among neurodegenerative diseases, in addition to nerve cell loss is inflammation. Although, a series of mutant genes and environmental toxins are related to neurodegenerative disorders, the causal mechanisms remain poorly understood.
Neurodegenerative diseases can be defined as multifactorial debilitating disorders of the nervous system. Overall, neurodegenerative diseases affect approximately 30 million individuals worldwide, according to the World Health Organization (WHO).
The factors contributing to the onset of neurodegenerative diseases are multiple. Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS) diseases are well-established as the consequence of misfolding and dysfunctional trafficking of proteins. However, other factors including mitochondrial dysfunction, oxidative stress, aging, and environmental issues are deeply associated with the onset of neurodegeneration.
Although all these factors have been demonstrated to significantly contribute to the etiology of common neurodegenerative diseases, some molecular mechanisms underlying neurodegeneration remain unveiled.
Present efforts are focused on the identification of viable drug targets and biomarkers for early diagnosis of the diseases, in order to develop the best suited therapies.
This research service, ‘Emerging Therapeutics for Neurodegenerative Diseases', focuses on the leading technology and business trends that are making possible the implementation of cutting-edge innovations that help to face the present and future challenges of the neurodegenerative disease therapeutics sector.
The tendencies depicted in this study will help to drive the sustainability of the neurodegenerative disease therapeutics industry by directly exhibiting the principal challenges faced by leading biopharmaceutical and biotechnology companies to develop new product modalities in an affordable and high performance style, while getting market acceptance and achieving market leadership by translating technology innovation to market competitiveness
The study covers the following topics:
An appendix is included, comprising lists of major industry influencers found in the field.